Clinical Trials · NCT03951831
REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- Mark Stein
- Enrollment
- 26
- Start date
- May 2019
- Locations
- 1 site, United States
- Primary endpoint
- Percentage of Subjects Achieving Undetectable PSA at 6 months after Combination Treatment